Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
Innate Pharma releases its financial calendar for 2020
Innate Pharma certified as a Great Place to Work®
Innate Pharma third quarter 2019 report
Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
Number of shares and voting rights of Innate Pharma as at November 1, 2019
Innate Pharma announces preclinical data presentations at SITC 2019
Innate Pharma announces closing of global offering
Innate Pharma announces the exercise in full of the option granted to the underwriters of its global offering and Nasdaq global select market listing to purchase 1,875,000 additional ADSs
Innate Pharma announces the pricing of its initial public offering on the Nasdaq global select market
